The threat of new tariffs on drugmakers has set off a debate within the biotech industry over whether to cut voluntary pricing deals with the Trump administration in exchange for exemptions.
Why it matters: Small and midsize companies don't have the resources of a Pfizer or Merck to make price cuts, domestic manufacturing investments and other concessions the White House is seeking.
